Jafron Biomedical's philanthropic practice was selected for inclusion in the Business for Good Case Collection 2025 on November 30th, officially released during the closing ceremony of 2025 Asia Philanthropy Forum.

Guided by the China NGO Network for International Exchanges and co-organized by THE ASIA ACADEMY OF PHILANTHROPY and partners, this year's forum brought together over 600 representatives of international organizations, government, and academia across 16 countries and regions. Attracting more than 900,000 online viewers, the discussion addressed the future of philanthropy in Asia as well as global sustainable development challenges.

Jafron is honored to be included in the Business for Good Case Collection 2025. This collection, jointly compiled by Yueer Philanthropy, CEIBS Centre for Wealth Management, and THE ASIA ACADEMY OF PHILANTHROPY, aims to present forward-thinking examples of how Chinese enterprises are advancing social responsibility through practical, high-impact initiatives.

*Common Prosperity, New Quality Productive Forces, Responsible Global Expansion, and Special Features — and includes nine representative Business for Good cases in total.

Starting from a domestic manufacturer of medical supplies, Jafron has broken the foreign technological monopolies in the blood purification industry with continued innovation, made high-quality technologies and healthcare services more accessible. With patients' welfare in mind, Jafron also initiated the "919 ESRD Day" to foster a broader public awareness and social consensus for those disadvantaged by diseases.

Beyond medical innovation, Jafron has expanded its corporate mission during its journey and taken on greater social responsibilities. It is delighted to see that Jafron's long-standing practice of "doing good with core capabilities" is recognized and affirmed through the case inclusion.

Over twenty years ago, Chinese patients with end-stage renal disease had only limited treatment options. To resolve the challenge posed by technological monopolies, Jafron dedicated many years to the development of more advanced blood purification therapies.

"Technological innovation means being one inch wide but one kilometer deep". In 2004, leveraging the "resin hemoadsorption" technology co-developed with Nankai University, China, Jafron launched the world's first hemoadsorption cartridge - HA130 - designed specifically for uremic patients.

*Jafron Biomedical’s independently developed and globally pioneering hemoadsorption technology

Redefining blood purification, Jafron has expanded the application of hemoadsorption techniques, allowing them to be adopted in more areas and with greater efficacy. Jafron's efforts also extend beyond research and production, as the company has established assistance programs for patients in financial difficulties and works constantly to reduce the cost of therapies with the support of national healthcare policies, supplying equipment and training for medical institutions in underdeveloped regions.

• 

  *Established the ‘Three-Basics Training Room’ in Milin City for training medical staff

  

  *The ‘Guangming Gesanghua’ Project: Free Vision Screening and Cataract Surgery

  
  

For more than twenty years, Jafron has remained committed to making hemoadsorption treatments more affordable, more accessible, and more effective. On September 19th, 2025, Jafron launched the "919 ESRD Day" in partnership with Xinhua News Agency, calling on society to pay more attention to this long-overlooked population living with chronic kidney disease.

Reflecting on its corporate journey, Jafron demonstrates to the industry that the mission and responsibility of a medical enterprise should go beyond research and manufacture, to create a better life for patients.

*Launch of the “919 ESRD Day” Public Welfare Initiative